• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Steven D. Colan, MD


  • Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, Yeh ET, Carver JR, Lipshultz SE, Minotti G, Armstrong GT, Cardinale D, Colan SD, Darby SC, Force TL, Kremer LC, Lenihan DJ, Sallan SE, Sawyer DB, Suter TM, Swain SM, van Leeuwen FE.Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014).Ecancermedicalscience. 2014;8:433.
  • Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, Oeffinger KC, Rosenthal DN, Sable CA, Sallan SE, Singh GK, Steinberger J, Cochran TR, Wilkinson JD, .Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.Circulation. 2013 Oct 22;128(17):1927-95.
  • Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB.Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.Cancer. 2013 Oct 1;119(19):3555-62.
  • Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE, .Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.Pediatrics. 2012 Dec;130(6):1003-11.
  • Chen MH, Colan SD, Diller L.Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers.Circ Res. 2011 Mar 4;108(5):619-28.
  • Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.Lancet Oncol. 2010 Oct;11(10):950-61.
  • Bacha EA, McElhinney DB, Guleserian KJ, Colan SD, Jonas RA, del Nido PJ, Marx GR.Surgical aortic valvuloplasty in children and adolescents with aortic regurgitation: acute and intermediate effects on aortic valve function and left ventricular dimensions.J Thorac Cardiovasc Surg. 2008 Mar;135(3):552-9, 559.e1-3.
  • Jacobs JP, Anderson RH, Weinberg PM, Walters HL 3rd, Tchervenkov CI, Del Duca D, Franklin RC, Aiello VD, Beland MJ, Colan SD, Gaynor JW, Krogmann ON, Kurosawa H, Maruszewski B, Stellin G, Elliott MJ.The nomenclature, definition and classification of cardiac structures in the setting of heterotaxy.Cardiol Young. 2007 Sep;17 Suppl 2:1-28. Review.
  • Vlahos AP, Marx GR, McElhinney D, Oneill S, Goudevenos I, Colan SD.Clinical utility of Doppler echocardiography in assessing aortic stenosis severity and predicting need for intervention in children.Pediatr Cardiol. 2008 May;29(3):507-14.
  • Minich LL, Sleeper LA, Atz AM, McCrindle BW, Lu M, Colan SD, Printz BF, Klein GL, Sundel RP, Takahashi M, Li JS, Vetter VL, Newburger JW.Delayed diagnosis of Kawasaki disease: what are the risk factors?.Pediatrics. 2007 Dec;120(6):e1434-40.
  • Brown DW, Gauvreau K, Powell AJ, Lang P, Colan SD, Del Nido PJ, Odegard KC, Geva T.Cardiac magnetic resonance versus routine cardiac catheterization before bidirectional glenn anastomosis in infants with functional single ventricle: a prospective randomized trial.Circulation. 2007 Dec 4;116(23):2718-25.
  • Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L.Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.Am Heart J. 2007 Oct;154(4):624-31.
  • Rhodes J, Margossian R, Darras BT, Colan SD, Jenkins KJ, Geva T, Powell AJ.Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy.Pediatr Cardiol. 2008 Mar;29(2):343-51.
  • Selamet Tierney ES, Wald RM, McElhinney DB, Marshall AC, Benson CB, Colan SD, Marcus EN, Marx GR, Levine JC, Wilkins-Haug L, Lock JE, Tworetzky W.Changes in left heart hemodynamics after technically successful in-utero aortic valvuloplasty.Ultrasound Obstet Gynecol. 2007 Oct;30(5):715-20.
  • McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, Vetter VL, Gersony WM, Mitchell PD, Newburger JW.Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements.Circulation. 2007 Jul 10;116(2):174-9.
  • Fernandes SM, Khairy P, Sanders SP, Colan SD.Bicuspid aortic valve morphology and interventions in the young.J Am Coll Cardiol. 2007 Jun 5;49(22):2211-4.
  • Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.J Clin Oncol. 2005 Apr 20;23(12):2629-36.
  • Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE.Cardiovascular Status in Long-Term Survivors of Hodgkin's Disease Treated With Chest Radiotherapy.J Clin Oncol. 2004 Aug 1;22(15):3139-48.
  • Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD.Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.J Clin Oncol. 2002 Mar 15;20(6):1677-82.
  • Moran AM, Lipshultz SE, Rifai N, O'Brien P, Mooney H, Perry S, Perez-Atayde A, Lipsitz SR, Colan SD.Non-invasive assessment of rejection in pediatric transplant patients: serologic and echocardiographic prediction of biopsy-proven myocardial rejection.J Heart Lung Transplant. 2000 Aug;19(8):756-64.
  • Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE.Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.J Clin Oncol. 1998 Feb;16(2):545-50.
  • Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD.Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.N Engl J Med. 1995 Jun 29;332(26):1738-43.
  • Hornberger LK, Sanders SP, Sahn DJ, Rice MJ, Spevak PJ, Benacerraf BR, McDonald RW, Colan SD.In utero pulmonary artery and aortic growth and potential for progression of pulmonary outflow tract obstruction in tetralogy of Fallot.J Am Coll Cardiol. 1995 Mar 1;25(3):739-45.
  • Lipshultz SE, Sanders SP, Goorin AM, Krischer JP, Sallan SE, Colan SD.Monitoring for anthracycline cardiotoxicity.Pediatrics. 1994 Mar;93(3):433-7.
  • Weindling SN, Wernovsky G, Colan SD, Parker JA, Boutin C, Mone SM, Costello J, Castaņeda AR, Treves ST.Myocardial perfusion, function and exercise tolerance after the arterial switch operation.J Am Coll Cardiol. 1994 Feb;23(2):424-33.
  • Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.N Engl J Med. 1991 Mar 21;324(12):808-15.
  • Parness IA, Yeager SB, Sanders SP, Benacerraf B, Colan SD, VanPraagh R.Echocardiographic diagnosis of fetal heart defects in mid trimester.Arch Dis Child. 1988 Oct;63(10 Spec No):1137-45.
  • Sanders SP, Chin AJ, Parness IA, Benacerraf B, Greene MF, Epstein MF, Colan SD, Frigoletto FD.Prenatal diagnosis of congenital heart defects in thoracoabdominally conjoined twins.N Engl J Med. 1985 Aug 8;313(6):370-4.
  • Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG.Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.N Engl J Med. 1985 Jun 20;312(25):1600-3.